Skip to main content

Table 2 Characteristics of the studies according to molecular subtypes

From: Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases

First author Year Patients Number Patient source Technique Type of patients HR estimation HR(95%CI) of OS HR(95%CI) of RFS
Vendrell 2008 33 France PCR ER positive BC Given by author 1.08 (0.40-2.88) 1.38 (0.60-3.21)
Ponzo 2009 60 Canada IHC Basal-like BC Given by author NA 3.02 (0.31-29.30)
   447 Canada IHC Nonbasal-like BC Given by author NA 1.49 (0.86-2.62)
Raghav 2012 64 USA RPPA TNBC Given by author NA 2.36 (0.86-6.51)
   140 USA RPPA hormone receptor positive BC Given by author 8.28 (1.10-62.59) 3.44 (1.21-9.81)
Gonzalez-Angulo 2013 173 USA MIP TNBC Given by author NA 1.33 (0.51-3.43)
   583 USA MIP hormone receptor positive BC Given by author NA 1.86 (1.07-3.25)
   207 USA MIP HER-2 positive BC Given by author NA 0.92 (0.29-2.95)
Zagouri 2013 170 Austria IHC TNBC Given by author 3.74(1.65-8.46) 3.43 (1.65-7.12)
Zagouri 2014 78 Austria IHC ER and HER-2 positive BC Given by author 1.32 (0.91-1.90) 1.22 (0.91-1.63)
Inanc 2014 97 Turkey IHC TNBC Given by author 1.15 (0.54-2.44) 2.05 (0.96-4.36)
  1. Note: IHC, immunohistochemistry; RPRP, Reverse phase protein lysate microarray; FISH, Fluorescence in situ hybridization; MIP, Molecular Inversion Probes; BC, breast cancer; TNBC, triple negative breast cancer; OS, over survival; RFS, Relapse-free survival; NA, not available.cpc